ONCOARENDI THERAPEUTICS
OncoArendi Therapeutics specialized in developing and commercializing of therapeutics for neoplastic and inflammatory diseases.
ONCOARENDI THERAPEUTICS
Industry:
Alternative Medicine Biotechnology Emergency Medicine Medical
Founded:
2012-01-01
Address:
Wysokie Mazowieckie, Podlaskie, Poland
Country:
Poland
Website Url:
http://www.oncoarendi.com
Total Employee:
101+
Status:
Active
Total Funding:
60.6 M PLN
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Apple Mobile Web Clips Icon Apache Mobile Non Scaleable Content Microsoft Exchange Online Office 365 Mail Facebook Sharer
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Current Employees Featured
Founder
Stock Details
Investors List
New Europe Ventures, LLC
New Europe Ventures, LLC investment in Series A - OncoArendi Therapeutics
Michał Sołowow
Michał Sołowow investment in Series A - OncoArendi Therapeutics
National Center for Research & Development
National Center for Research & Development investment in Grant - OncoArendi Therapeutics
Medical University of Warsaw
Medical University of Warsaw investment in Grant - OncoArendi Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-27 | OncoArendi Therapeutics Appoints Samson Fung, M.D. as Chief Medical Officer |
Official Site Inspections
http://www.oncoarendi.com
- Host name: shared-aky43.rev.nazwa.pl
- IP address: 85.128.156.43
- Location: Poland
- Latitude: 52.2394
- Longitude: 21.0362
- Timezone: Europe/Warsaw
More informations about "OncoArendi Therapeutics" on Search Engine
OncoArendi Therapeutics Gets Listed - Molecure
OncoArendi Therapeutics S.A., an innovative, clinical stage, biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics for cancer …See details»
Organization and comprehensive execution of the phase I, First …
OncoArendi Therapeutics S. A. ul. Żwirki i Wigury 101 02-089 Warsaw VAT ID: 728 27 89 248 Contact persons Kinga Jabłońska (formerly Woźniak) e-mail: …See details»
OncoArendi Therapeutics Company Profile - Craft
Mar 25, 2022 OncoArendi Therapeutics has 5 employees across 2 locations. See insights on OncoArendi Therapeutics including office locations, competitors, revenue, …See details»
OncoArendi Therapeutics Reports Continued Strategic and
Warsaw, Poland, 25 March 2022 – OncoArendi Therapeutics S.A. (”OncoArendi”; WSE: OAT), a clinical stage biopharmaceutical company that uses its world leading medicinal …See details»
OncoArendi Therapeutics - Crunchbase Company Profile & Funding
OncoArendi Therapeutics specializes in developing and commercializing of therapeutics for neoplastic and inflammatory diseases. OncoArendi Therapeutics is a …See details»
OncoArendi Therapeutics Reports Continued Strategic and …
Mar 25, 2022 OncoArendi is a clinical stage biopharmaceutical company that uses its world leading medicinal chemistry capabilities to discover and develop first in class small …See details»
OncoArendi Therapeutics is significantly moving closer to the …
February 08, 2022 at 06:30 am EST. OncoArendi has received scientific advice from the European Medicines Agency (EMA) on the clinical development of OATD-02 and has …See details»
OncoArendi Therapeutics as Platform-based Polish Biotech …
OncoArendi Therapeutics SA (OAT) has been founded in 2012 as USstyle biotech operating in Poland. From the beginning, OAT has been focused on first-in-class or best …See details»
OncoArendi Therapeutics
In 2022E, we forecast OncoArendi will receive a milestone of EUR 3m from Galapagos. We expect Phase 2 study in idiopathic pulmonary fibrosis (IPF) to be completed in 2024E …See details»
OncoArendi Therapeutics to Begin the Phase 1 Clinical …
OncoArendi Therapeutics is an innovative biopharmaceutical company dedicated to developing and commercializing novel therapeutics for inflammatory diseases associated …See details»
OncoArendi Therapeutics Announces a License Option …
11 March 2022 – OncoArendi Therapeutics S.A. (”OncoArendi”; WSE: OAT), a clinical stage biotechnology company that uses its world leading medicinal chemistry capabilities …See details»
OncoArendi Therapeutics Appoints Dr. Adam Gołębiowski, Dr.
WARSAW, Poland, Jan. 31, 2022 /PRNewswire/ -- OncoArendi Therapeutics S.A. ("OncoArendi"; WSE: OAT), a clinical stage biotechnology company that uses its world …See details»
OncoArendi Therapeutics Reports Continued Strategic and …
Warsaw, Poland, 25 March 2022 – OncoArendi Therapeutics S.A. (”OncoArendi”; WSE: OAT), a clinical stage biopharmaceutical company that uses its world leading medicinal …See details»
Joint MSU/UofM IP acquired by OncoArendi Therapeutics
11 March 2022 – OncoArendi Therapeutics S.A. (”OncoArendi”; WSE: OAT), a clinical stage biotechnology company that uses its world leading medicinal chemistry capabilities …See details»
OncoArendi Therapeutics Announces a License Option …
Mar 11, 2022 OncoArendi is a clinical stage biotechnology company that uses its world leading medicinal chemistry capabilities to discover and develop first in class small …See details»
OncoArendi and Galapagos enter into exclusive collaboration
Nov 5, 2020 OncoArendi Therapeutics SA (WSE:OAT) is a Polish innovative biotechnology company specializing in research, development and commercialization of …See details»
OncoArendi Therapeutics - Funding, Financials, Valuation
OncoArendi Therapeutics specializes in developing and commercializing of therapeutics for neoplastic and inflammatory diseases.See details»
OncoArendi Therapeutics - Contacts, Employees, Board …
OncoArendi Therapeutics specializes in developing and commercializing of therapeutics for neoplastic and inflammatory diseases.See details»
OncoArendi Therapeutics has received the final report from the …
OncoArendi Therapeutics is the first and so far only biotechnology company in the world, which conducts clinical trials of drug candidates targeting chitinase (first-in-class). the …See details»
OncoArendi Therapeutics - Crunchbase
OncoArendi Therapeutics specializes in developing and commercializing of therapeutics for neoplastic and inflammatory diseases.See details»